Eli Lilly Seeks Agreement with U.K. Government to Raise Prices for Medicines: Report

Key Takeaways

• Lilly seeks higher NHS drug prices and rebate reforms
• Current VPAG rebates now 25‑33% of revenues, up from 5%
• Potential price hikes could affect UK launch and manufacturing decisions
• Outcomes‑based pricing may tie reimbursement to patient work‑return

Summary

Eli Lilly is negotiating with the U.K. government to raise NHS drug prices and overhaul the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG). The company argues that current rebate rates of 25‑33% of revenues are unsustainable and threaten future investment, launch, and manufacturing decisions. Lilly also proposes outcomes‑based pricing models, linking reimbursement to patient health and work‑return metrics. Negotiations are ongoing, with officials hopeful for an agreement by summer 2026.

Pulse Analysis

The United Kingdom’s drug‑pricing framework has become a flashpoint for the pharma sector, with the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) demanding rebates that now consume a quarter to a third of branded‑drug revenues. This steep escalation—from roughly 5% in 2021 to 25‑33% today—has squeezed profit margins and prompted companies to reassess the commercial viability of the market. Policymakers argue that the scheme protects the NHS budget, yet industry leaders contend it undermines the country’s ambition to be a hub for life‑science innovation.

Eli Lilly’s latest push exemplifies the growing tension. The firm is urging the Department of Health and Social Care to adopt regular price increases for NHS‑listed medicines and to phase out key VPAG components. In parallel, Lilly is exploring outcomes‑based pricing, where reimbursement for therapies such as its anti‑obesity drug Mounjaro would depend on measurable patient benefits, including return to work. The company’s 170% price hike for Mounjaro in 2025 illustrates its willingness to test price flexibility when market access is at stake. Other major players, from AstraZeneca to GSK, have voiced similar concerns, citing recent withdrawals of multi‑hundred‑million‑dollar investments.

The stakes extend beyond individual contracts. If the UK adopts a more balanced pricing regime, it could revive stalled R&D pipelines, safeguard jobs in manufacturing, and maintain the NHS’s access to cutting‑edge treatments. Conversely, a stalemate may drive firms to prioritize markets with clearer profit pathways, eroding the UK’s competitive edge in the global pharma landscape. Stakeholders will be watching the summer negotiations closely, as the outcome will likely set a precedent for how high‑income economies reconcile public‑health budgets with the financial realities of drug development.